Tocilizumab role in reducing the complications of COVID patients

Phase 3

• Conditions: Pneumonia due to COVID-19; B34.2

• Registration Number: RBR-25rtydq
• Lead Sponsor: ady Reading Hospital-MTI Peshawar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-08-30
• Study Start: 2021-08-11
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Confirmed or suspected SARS-CoV infection; Adult patient; Moderate to Critical COVID Patients

Exclusion Criteria

Known hypersensitivity to Tocilizumab or its excipients; patient below 18 years; mild cases of Confirmed or suspected SARS-CoV

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of mortality in patients receiving tocilizumab in the hospital, verified by chi square test, it was observed that patients receiving invasive respiratory support were identified to higher risk of mortality than patients receiving oxygen support ( (50 vs 86, p<0.05)

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are not expected